SCHEMBL5111149

SCHEMBL5111149

O=S(=O)(Nc1nc(Cl)cnc1OCc1ccccn1)c1ccc(Cl)s1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR4 P51679 9/20 0.48
CCR5 P51681 2/20 0.48
NFKBIA P25963 1/20 0.45
RELA Q04206 1/20 0.45
KMT2A Q03164 6/20 0.44
MEN1 O00255 5/20 0.44
THRB P10828 1/20 0.44
BLM P54132 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
LMNA P02545 2/20 0.42
CRHBP P24387 1/20 0.42
HTT P42858 1/20 0.42
CRHR2 Q13324 1/20 0.42
PABPC1 P11940 1/20 0.40
KDM4E B2RXH2 1/20 0.40
NPC1 O15118 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5106613 0.88 CCR4 (0.47) CCR4CCR5NFKBIARELAKMT2A
SCHEMBL6182891 0.86 KDM4E (0.48) CCR4NFKBIARELAKMT2AMEN1
SCHEMBL6605601 0.81 CCR5 (0.54) CCR4CCR5NFKBIARELAKMT2A
SCHEMBL5103326 0.81 CCR4 (0.48) CCR4CCR5NFKBIARELAKMT2A
SCHEMBL5102814 0.81 CCR5 (0.50) CCR4CCR5NFKBIARELAKMT2A
SCHEMBL1731933 0.80 CCR4 (0.67) CCR4
SCHEMBL5103322 0.79 CCR5 (0.71) CCR4CCR5KMT2AMEN1PABPC1
SCHEMBL6606135 0.77 CCR4 (0.41) CCR4CCR5KMT2AMEN1THRB
SCHEMBL6185129 0.75 CCR4 (0.37) CCR4KMT2AMEN1NPC1ALDH1A1
SCHEMBL1733169 0.73 CCR4 (0.71) CCR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7410972-B2 Compounds ASTRAZENECA AB (SE) 2008-08-12 US claimed
EP-1458715-B1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2005-12-07 EP claimed
US-20050075346-A1 Novel compounds ASTRAZENECA AB (SE) 2005-04-07 US claimed
US-7410972-B2 Compounds ASTRAZENECA AB (SE) 2008-08-12 US disclosed
US-7410972-B2 Compounds ASTRAZENECA AB (SE) 2008-08-12 US disclosed
US-7410972-B2 Compounds ASTRAZENECA AB (SE) 2008-08-12 US disclosed
EP-1458715-B1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2005-12-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075346-A1 Novel compounds CCL11, CCL2, CCL5 CCR4 22/4885CCR5 10/4885NFKBIA 190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.